Cash Flow Statement (Annual)

LPTN / Lpath, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss - - - - - -27,431 -41,167
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletionand Amortization Excluding Deferred Finance Costs - - - - - 8,060 9,092
    Amortization Of Financing Costs - - - - - 886 425
    Paid In Kind Interest - - - - - 4,560 13,317
    Provision For Doubtful Accounts - - - - - 387 331
    Inventory Write Down - - - - - -54 3,750
    Share Based Compensation 1,032 702 600 837 1,236 953 381
    Foreign Currency Transaction Gain Loss Before Tax - - - - - -522 -1,332
    Increase Decrease In Operating Capital
      Increase Decrease In Accounts Receivable 15,049 -14,056 -1,101 1,076 -583 -720 426
      Increase Decrease In Inventories - - - - - 6,352 3,054
      Increase Decrease In Prepaid Deferred Expense And Other Assets -14 165 -24 -15 121 -56 -327
      Increase Decrease In Accounts Payable And Accrued Liabilities 1,602 1,228 -840 -179 1,101 -3,047 523
  Net Cash Provided By Used In Operating Activities - - - - - -16,005 -12,901
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 2 134 155 45 106 21 1,028
  Payments To Acquire Intangible Assets 467 355 190 346 430 270 1,337
  Net Cash Provided By Used In Investing Activities - - - - - -6,926 -2,165
Net Cash Provided By Used In Financing Activities
  Proceeds From Stock Options Exercised 24 34 74 16 0 48 53
  Proceeds From Issuance Of Common Stock - - - 803 9,730 0 29,000
  Payments Of Financing Costs - - - - - 1,088 216
  Repayments Of Long Term Debt - - - - - 37,717 11,220
  Net Cash Provided By Used In Financing Activities - - - - - 33,484 12,617
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - -
Supplemental Cash Flow Information
  Interest Paid - - - - - 4,965 5,791
  Income Taxes Paid - 2 2 2 2 2 318

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 03767D108